These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Novel, achiral 1,3,4-benzotriazepine analogues of 1,4-benzodiazepine-based CCK(2) antagonists that display high selectivity over CCK(1) receptors. McDonald IM; Austin C; Buck IM; Dunstone DJ; Griffin E; Harper EA; Hull RA; Kalindjian SB; Linney ID; Low CM; Pether MJ; Spencer J; Wright PT; Adatia T; Bashall A J Med Chem; 2006 Apr; 49(7):2253-61. PubMed ID: 16570921 [TBL] [Abstract][Full Text] [Related]
6. Toward the identification of a reliable 3D QSAR pharmacophore model for the CCK2 receptor antagonism. Gupta AK; Varshney K; Saxena AK J Chem Inf Model; 2012 May; 52(5):1376-90. PubMed ID: 22530718 [TBL] [Abstract][Full Text] [Related]
7. Anthranilic sulfonamide CCK1/CCK2 dual receptor antagonists II: tuning of receptor selectivity and in vivo efficacy. Pippel M; Boyce K; Venkatesan H; Phuong VK; Yan W; Barrett TD; Lagaud G; Li L; Morton MF; Prendergast C; Wu X; Shankley NP; Rabinowitz MH Bioorg Med Chem Lett; 2009 Nov; 19(22):6376-8. PubMed ID: 19815410 [TBL] [Abstract][Full Text] [Related]
8. Synthesis of new arylpiperazinylalkylthiobenzimidazole, benzothiazole, or benzoxazole derivatives as potent and selective 5-HT1A serotonin receptor ligands. Siracusa MA; Salerno L; Modica MN; Pittalà V; Romeo G; Amato ME; Nowak M; Bojarski AJ; Mereghetti I; Cagnotto A; Mennini T J Med Chem; 2008 Aug; 51(15):4529-38. PubMed ID: 18598015 [TBL] [Abstract][Full Text] [Related]
9. Heterocyclic 1,7-disubstituted indole sulfonamides are potent and selective human EP3 receptor antagonists. Hategan G; Polozov AM; Zeller W; Cao H; Mishra RK; Kiselyov AS; Ramirez J; Halldorsdottir G; Andrésson T; Gurney ME; Singh J Bioorg Med Chem Lett; 2009 Dec; 19(23):6797-800. PubMed ID: 19836233 [TBL] [Abstract][Full Text] [Related]
10. Scaffold hopping with molecular field points: identification of a cholecystokinin-2 (CCK2) receptor pharmacophore and its use in the design of a prototypical series of pyrrole- and imidazole-based CCK2 antagonists. Low CM; Buck IM; Cooke T; Cushnir JR; Kalindjian SB; Kotecha A; Pether MJ; Shankley NP; Vinter JG; Wright L J Med Chem; 2005 Nov; 48(22):6790-802. PubMed ID: 16250638 [TBL] [Abstract][Full Text] [Related]
11. Synthesis and evaluation of benzothiazole-based analogues as novel, potent, and selective fatty acid amide hydrolase inhibitors. Wang X; Sarris K; Kage K; Zhang D; Brown SP; Kolasa T; Surowy C; El Kouhen OF; Muchmore SW; Brioni JD; Stewart AO J Med Chem; 2009 Jan; 52(1):170-80. PubMed ID: 19072118 [TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of novel sulfonamide-containing bradykinin hB2 receptor antagonists. 1. Synthesis and SAR of alpha,alpha-dimethylglycine sulfonamides. Fattori D; Rossi C; Fincham CI; Berettoni M; Calvani F; Catrambone F; Felicetti P; Gensini M; Terracciano R; Altamura M; Bressan A; Giuliani S; Maggi CA; Meini S; Valenti C; Quartara L J Med Chem; 2006 Jun; 49(12):3602-13. PubMed ID: 16759102 [TBL] [Abstract][Full Text] [Related]
13. Synthesis, SAR, and X-ray structure of tricyclic compounds as potent FBPase inhibitors. Tsukada T; Takahashi M; Takemoto T; Kanno O; Yamane T; Kawamura S; Nishi T Bioorg Med Chem Lett; 2009 Oct; 19(20):5909-12. PubMed ID: 19762234 [TBL] [Abstract][Full Text] [Related]
14. Synthesis of novel inhibitors of β-glucuronidase based on benzothiazole skeleton and study of their binding affinity by molecular docking. Khan KM; Rahim F; Halim SA; Taha M; Khan M; Perveen S; Zaheer-Ul-Haq ; Mesaik MA; Iqbal Choudhary M Bioorg Med Chem; 2011 Jul; 19(14):4286-94. PubMed ID: 21684753 [TBL] [Abstract][Full Text] [Related]
15. Achiral, selective CCK2 receptor antagonists based on a 1,3,5-benzotriazepine-2,4-dione template. Spencer J; Gaffen J; Griffin E; Harper EA; Linney ID; McDonald IM; Roberts SP; Shaxted ME; Adatia T; Bashall A Bioorg Med Chem; 2008 Mar; 16(6):2974-83. PubMed ID: 18289857 [TBL] [Abstract][Full Text] [Related]
16. Discovery and optimisation of a potent and selective tertiary sulfonamide oxytocin antagonist. Barton NP; Bellenie BR; Doran AT; Emmons AJ; Heer JP; Salvagno CM Bioorg Med Chem Lett; 2009 Jan; 19(2):528-32. PubMed ID: 19081251 [TBL] [Abstract][Full Text] [Related]
17. Reassessing the melatonin pharmacophore--enantiomeric resolution, pharmacological activity, structure analysis, and molecular modeling of a constrained chiral melatonin analogue. Rivara S; Diamantini G; Di Giacomo B; Lamba D; Gatti G; Lucini V; Pannacci M; Mor M; Spadoni G; Tarzia G Bioorg Med Chem; 2006 May; 14(10):3383-91. PubMed ID: 16431121 [TBL] [Abstract][Full Text] [Related]
18. Ligand-based molecular modeling study on a chemically diverse series of cholecystokinin-B/gastrin receptor antagonists: generation of predictive model. Chopra M; Mishra AK J Chem Inf Model; 2005; 45(6):1934-42. PubMed ID: 16309300 [TBL] [Abstract][Full Text] [Related]
19. Benzothiazole-based N-(phenylsulfonyl)amides as a novel family of PPARα antagonists. Ammazzalorso A; Giancristofaro A; D'Angelo A; Filippis BD; Fantacuzzi M; Giampietro L; Maccallini C; Amoroso R Bioorg Med Chem Lett; 2011 Aug; 21(16):4869-72. PubMed ID: 21742490 [TBL] [Abstract][Full Text] [Related]
20. Potent nonpeptide antagonists of the bradykinin B1 receptor: structure-activity relationship studies with novel diaminochroman carboxamides. Biswas K; Li A; Chen JJ; D'Amico DC; Fotsch C; Han N; Human J; Liu Q; Norman MH; Riahi B; Yuan C; Suzuki H; Mareska DA; Zhan J; Clarke DE; Toro A; Groneberg RD; Burgess LE; Lester-Zeiner D; Biddlecome G; Manning BH; Arik L; Dong H; Huang M; Kamassah A; Loeloff R; Sun H; Hsieh FY; Kumar G; Ng GY; Hungate RW; Askew BC; Johnson E J Med Chem; 2007 May; 50(9):2200-12. PubMed ID: 17408249 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]